Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Technically, Tandem Diabetes Care Inc. (NASDAQ: TNDM) provides opportunities for traders who are watching the price of the stock oscillate over time.

Instead of using the controversial body mass index, or BMI, to assess weight, an international group of scientists proposes ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

A new error grid to assess the accuracy of glucose measurements could give continuous glucose monitor manufacturers and ...

The claim that ragi is inherently diabetes-friendly is misleading. Excessive consumption can lead to blood sugar spikes and ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Obesity affects over 1 billion people globally, with 40 percent of U.S. adults classified as obese under the present ...

New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetesRUTHE ...

By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that ...